Topas Therapeutics GmbH

Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying treatments for autoimmune and inflammatory diseases. At Topas we are developing a proprietary platform of antigen-specific nanoparticle conjugates, called TPCs (Topas Particle Conjugates) uniquely positioned to address major unmet need in T-cell mediated diseases in a targeted manner. TPCs are uniquely engineered to restore and promote immune tolerance by targeting liver sinusoidal endothelial cells (LSECs) and harnessing antigen-specific immune tolerance mechanisms of the liver. Our technology has delivered to date two clinical candidates: TPM203 (Phase 1 pemphigus vulgaris) and TPM 502 (Phase 2 celiac disease).